Acceleron Pharma Inc
Change company Symbol lookup
Select an option...
XLRN Acceleron Pharma Inc
INCT Incapta Inc
BML-J Bank of America Corp
PEP PepsiCo Inc
AGNC Agnc Investment Corp
ACM AECOM
CLSN Celsion Corp
BAC Bank of America Corp
GPHBF Graphene 3D Lab Inc(British Columbia)
ITRI Itron Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Closing Price
$126.19
Day's Change
-0.78 (-0.61%)
Bid
--
Ask
--
B/A Size
--
Day's High
129.78
Day's Low
124.97
Volume
(Average)
Volume:
379,658

10-day average volume:
398,723
379,658

Display:

Providers:

UpdateCancel
6 providers
January 04, 2021
Acceleron to Participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced that Habib Dable, Acceleron's President and Chief Executive Officer, will present a corporate overview during the 39th Annual J.P. Morgan Healthcare Conference. The presentation will take place on...(BusinessWire)

December 14, 2020
Acceleron Receives Orphan Designation from the European Commission (EC) for Sotatercept in Pulmonary Arterial Hypertension (PAH)

--- In the spring of 2020, sotatercept received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), both in PAH - Acceleron Pharma Inc. (Nasdaq: XLRN), a...(BusinessWire)

December 01, 2020
Acceleron Receives FDA Orphan Drug Designation for ACE-1334 for the Treatment of Systemic Sclerosis

--- ACE-1334 previously received Fast Track designation from the FDA - Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat...(BusinessWire)

November 13, 2020
Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions

--- Sotatercept was generally well tolerated, consistent with the previously reported safety profile in PAH and in other diseases - --- Acceleron to host investor and analyst conference call and webcast with guest PAH key opinion leaders today...(BusinessWire)

Acceleron Presents New Data from the PULSAR Phase 2 Trial, Preclinical Research on Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association (AHA) Scientific Sessions

--- Presentation of echocardiography data from the PULSAR trial received AHA's "Cardiopulmonary Best Abstract" Award - --- Preclinical research shows sotatercept inhibits cardiac remodeling, restores function in experimental model of severe PAH - (BusinessWire)

November 09, 2020
Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions

--- AHA sessions to include data from the ongoing SPECTRA Phase 2 trial - --- Acceleron to host investor and analyst conference call and webcast with guest PAH key opinion leaders on Friday, November 13, at 11:00 a.m. EST - (BusinessWire)

November 05, 2020
Acceleron Pharma, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 5, 2020 / Acceleron Pharma, Inc. (NASDAQ:XLRN) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 5, 2020 at 5:00 PM Eastern Time. (Accesswire)

Acceleron Reports Third Quarter 2020 Operating and Financial Results

--- REBLOZYL, the first and only erythroid maturation agent, was approved by Health Canada for the treatment of transfusion-dependent anemia in adults with beta-thalassemia - --- Registrational STELLAR Phase 3 trial of sotatercept in patients with...(BusinessWire)

Acceleron Announces Third Quarter 2020 REBLOZYL(R) Net Sales

--- Acceleron will report its full third quarter 2020 financial and operating results after the close of U.S. financial markets today, November 5, 2020, with its webcast and conference call starting at 5:00 p.m. EST - (BusinessWire)

November 04, 2020
Acceleron Announces REBLOZYL(R) (luspatercept-aamt) Virtual Presentations at the 62nd American Society of Hematology Annual Meeting

--- Longitudinal analyses from the BELIEVE trial show reductions in red blood cell transfusions and iron chelation therapy in luspatercept-treated patients - --- Longer-term update from Phase 2 trial finds durable response to luspatercept treatment...(BusinessWire)

October 26, 2020
Acceleron to Webcast Third Quarter 2020 Operating and Financial Results on November 5, 2020

Acceleron Pharma Inc. (Nasdaq:XLRN) today announced it will host a webcast and conference call on Thursday, November 5, 2020 at 5:00 p.m. EST to discuss its third quarter 2020 operating and financial results. (BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.